A prospective clinical and pathological examination of injection site reactions with the HIV-1 fusion inhibitor enfuvirtide

Antiviral Therapy

Volumn 11, Issue 7, 2006, Pages 935-939

  Myers, Sarah A ^a   Selim, Angelica A ^a   McDaniel, Margaret A ^a   Hall, Russell ^a   Zhang, Ying ^b   Bartlett, John A ^a   True, Andrea L ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b Trimeris Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENFUVIRTIDE; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR;

ABDOMEN; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL EXAMINATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REGIMEN; ECCHYMOSIS; EOSINOPHIL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; INJECTION SITE DISCOMFORT; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE REACTION; LYMPHOCYTIC INFILTRATION; MALE; NEUTROPHIL; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; PUNCH BIOPSY; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE;

ABDOMEN; ADULT; BIOPSY; COHORT STUDIES; HIV ENVELOPE PROTEIN GP41; HIV FUSION INHIBITORS; HIV INFECTIONS; HIV-1; HUMANS; INJECTIONS, INTRAPERITONEAL; LEUKOCYTES; MALE; MIDDLE AGED; PAIN; PEPTIDE FRAGMENTS; PROSPECTIVE STUDIES; TIME FACTORS;

EID: 33750945439     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Kilby JM, Hopkins S, Venetta TM, et al. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat Med 1998; 4:1302-1307.
2. Wild C, Greenwell T, Matthews T. A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion. AIDS Res Hum Retroviruses 1993; 9:1051-1053.
3. Church JA, Hughes M, Chen J, et al. Pediatric AIDS Clinical Trials Group P1005 Study Team. Long term tolerability and safety of enfuvirtide for human immunodeficiency virus 1-infected children. Pediatr Infect Dis J 2004; 23:713-718.
4. Katlama C, Arastéh K, Clotet B, et al. Enfuvirtide TORO studies: 48 week results confirm 24 week findings. 2nd International AIDS Society Meeting. 13-16 July 2003, Paris, France. Abstract LB2.
5. Kilby JM, Lalezari JP, Eron JJ, et al. The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults. AIDS Res Hum Retroviruses 2002; 18:685-693.
6. Lalezari JP, Henry K, O'Hearn M, et al. TORO 1 Study Group. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 2003; 348:2175-2185.
7. Lalezari JP, DeJesus E, Northfelt DW, et al. A controlled Phase II trial assessing three doses of enfuvirtide (T-20) in combination with abacavir, amprenavir, ritonavir and efavirenz in non-nucleoside reverse transcriptase inhibitor-naive HIV-infected adults. Antivir Ther 2003; 8:279-287.
8. Lalezari JP, Eron JJ, Carlson M, et al. A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy. AIDS 2003; 17:691-698.
9. Arasteh, K, Lazzarin, A, Clotet, B. TORO: 96 week virological and immunological response and safety evaluation of enfuvirtide with n optimized background regimen. The XV International AIDS Conference. 11-16 July 2004. Bangkok, Thailand. Abstract MoOrB1058
10. Lalezari JP, Patel I, Zhang X, et al. Influence of subcutaneous injection site on the steady-state pharmacokinetics of enfuvirtide (T-20) in HIV-1 infected subjects. J Clin Virol 2003: 28:217-222.
11. Walmsley S, Henry K, Katlama C, et al. Enfuvirtide (T-20) cross-reactive glycoprotein 41 antibody does not impair the efficacy or safety or enfuvirtide. J Infect Dis 2003; 188:1827-1833.
12. Ball RA, Kinchelow T. Pathology of injection site reactions with enfuvirtide. J Am Acad Dermatol 2003; 49:826-831.
13. Allergy: Principles and Practice. Edited by Middleton. St Louis: Mosby-Year Book, Inc, 1998.
14. Zeltser R, Valle L, Tanck C, Holyst MM, Ritchlin C, Gaspari AA. Clinical, histological, and immunophenotypic characteristics of injection site reactions associated with etanercept: a recombinant tumor necrosis factor alpha receptor: Fc fusion protein. Arch Dermatol 2001; 137:893-899.
15. Maggi P, Ladisa N, Cinori E, Altobella A, Pastore G, Filotico R. Cutaneous injection site reactions to long-term therapy with enfuvirtide. J Antimicrob Chemother 2004; 53:678-681.
16. Jorgensen JT, Romsing J, Rasmussen M, Moller-Sonnergaard J, Vang L, Musaeus L. Pain assessment of subcutaneous injections. Ann Pharmacother 1996; 30:729-732.